This expansion is largely fueled by the pharmaceutical and biotechnology sectors, which accounted for 44% of market demand in 2025. Researchers are increasingly relying on high-resolution mass spectrometry and next-generation sequencing to conduct comprehensive molecular profiling. As AI, machine learning, and cloud-based bioinformatics tools improve, the ability to interpret complex cross-omics data has become a critical driver for drug discovery and clinical research.

North America currently maintains the lead, holding 44.2% of the market share in 2025. This dominance is supported by a robust infrastructure of research institutions and significant institutional funding for life sciences. While sequencing technologies remain the largest segment by technology type, spatial omics is emerging as the fastest-growing field, with a projected CAGR of 13.8% through 2031. Major industry participants, including Illumina, Thermo Fisher Scientific, and 10x Genomics, continue to refine their platforms to meet the rising demand for scalable and high-throughput analytical solutions.